O	0	8	Superior
O	9	16	outcome
O	17	22	after
B-intervention	23	34	neoadjuvant
I-intervention	35	47	chemotherapy
I-intervention	48	52	with
I-intervention	53	62	docetaxel
I-intervention	62	63	,
I-intervention	64	77	anthracycline
I-intervention	77	78	,
I-intervention	79	82	and
I-intervention	83	99	cyclophosphamide
O	100	106	versus
B-control	107	116	docetaxel
I-control	117	121	plus
I-control	122	138	cyclophosphamide
O	138	139	:
O	140	147	results
O	148	152	from
O	153	156	the
O	157	161	NATT
O	162	167	trial
O	168	170	in
O	171	177	triple
O	178	186	negative
O	187	189	or
O	190	194	HER2
O	195	203	positive
O	204	210	breast
O	211	217	cancer
O	217	218	.

O	219	222	The
O	223	230	purpose
O	231	233	of
O	234	238	this
O	239	244	study
O	245	247	is
O	248	250	to
O	251	259	evaluate
O	260	263	the
O	264	272	efficacy
O	273	276	and
O	277	283	safety
O	284	286	of
O	287	296	docetaxel
O	297	301	plus
O	302	318	cyclophosphamide
O	318	319	(
O	319	321	TC
O	321	322	)
O	323	331	compared
O	332	336	with
O	337	346	docetaxel
O	346	347	,
O	348	361	anthracycline
O	361	362	,
O	363	366	and
O	367	383	cyclophosphamide
O	383	384	(
O	384	387	TEC
O	387	388	)
O	389	391	in
O	392	403	neoadjuvant
O	404	413	treatment
O	414	416	of
O	417	423	triple
O	424	432	negative
O	433	435	or
O	436	440	HER2
O	441	449	positive
O	450	456	breast
O	457	463	cancer
O	463	464	.

O	465	473	Eligible
O	474	480	breast
O	481	487	cancer
O	488	496	patients
O	497	501	were
O	502	512	randomized
O	513	515	to
O	516	523	receive
O	524	527	six
O	528	534	cycles
O	535	537	of
O	538	540	TC
O	541	543	or
O	544	547	TEC
O	547	548	.

O	549	552	The
O	553	560	primary
O	561	564	end
O	565	570	point
O	571	574	was
B-outcome-Measure	575	587	pathological
I-outcome-Measure	588	596	complete
I-outcome-Measure	597	606	remission
I-outcome-Measure	607	608	(
I-outcome-Measure	608	611	pCR
I-outcome-Measure	611	612	)
O	612	613	.

O	614	623	Secondary
O	624	627	end
O	628	634	points
O	635	643	included
B-outcome-Measure	644	650	safety
O	650	651	,
B-outcome-Measure	652	660	clinical
I-outcome-Measure	661	669	response
I-outcome-Measure	670	674	rate
O	674	675	,
O	676	679	and
B-outcome-Measure	680	688	survival
I-outcome-Measure	689	696	outcome
O	696	697	.

B-total-participants	698	701	One
I-total-participants	702	709	hundred
I-total-participants	710	713	and
I-total-participants	714	717	two
O	718	726	patients
O	727	731	were
O	732	741	initially
O	742	752	randomized
O	753	756	and
B-total-participants	757	759	96
O	760	768	patients
O	769	773	were
O	774	783	available
O	784	787	for
O	788	796	efficacy
O	797	805	analysis
O	805	806	.

O	807	809	96
O	809	810	.
O	810	811	9
O	812	813	%
O	814	822	patients
O	823	827	were
O	828	835	treated
O	836	840	with
O	841	851	epirubicin
O	852	854	as
O	855	857	an
O	858	871	anthracycline
O	872	877	agent
O	877	878	.

B-outcome	879	882	pCR
I-outcome	883	888	rates
O	889	893	were
B-iv-bin-percent	894	895	6
I-iv-bin-percent	895	896	.
I-iv-bin-percent	896	897	8
I-iv-bin-percent	898	899	%
O	900	901	(
B-iv-bin-abs	901	902	3
O	902	903	/
B-intervention-participants	903	905	45
O	905	906	)
O	907	910	and
B-cv-bin-percent	911	913	17
I-cv-bin-percent	913	914	.
I-cv-bin-percent	914	915	6
I-cv-bin-percent	916	917	%
O	918	919	(
B-cv-bin-abs	919	920	9
O	920	921	/
B-control-participants	921	923	51
O	923	924	)
O	925	927	in
O	928	930	TC
O	931	934	and
O	935	938	TEC
O	939	944	group
O	944	945	,
O	946	958	respectively
O	958	959	,
O	960	961	P
O	962	963	=
O	964	965	0
O	965	966	.
O	966	969	113
O	969	970	.

O	971	976	After
O	977	978	a
O	979	983	mean
O	984	990	follow
O	991	993	up
O	994	996	of
O	997	999	20
O	1000	1001	(
O	1001	1002	3
O	1002	1003	–
O	1003	1005	36
O	1005	1006	)
O	1007	1013	months
O	1013	1014	,
O	1015	1018	non
O	1018	1019	-
O	1019	1032	anthracycline
O	1032	1033	-
O	1033	1043	containing
O	1044	1046	TC
O	1047	1054	regimen
O	1055	1064	treatment
O	1065	1073	resulted
O	1074	1076	in
O	1077	1078	a
O	1079	1084	worse
B-outcome	1085	1090	event
I-outcome	1091	1095	free
I-outcome	1096	1104	survival
O	1105	1106	(
O	1106	1114	adjusted
O	1115	1121	hazard
O	1122	1127	ratio
O	1128	1129	[
O	1129	1131	HR
O	1131	1132	]
O	1133	1134	2
O	1134	1135	.
O	1135	1137	42
O	1137	1138	;
O	1139	1141	95
O	1142	1143	%
O	1144	1147	CI1
O	1147	1148	.
O	1148	1150	11
O	1150	1151	–
O	1151	1152	5
O	1152	1153	.
O	1153	1155	30
O	1155	1156	)
O	1157	1160	and
B-outcome	1161	1168	disease
I-outcome	1168	1169	-
I-outcome	1169	1173	free
I-outcome	1174	1182	survival
O	1183	1184	(
O	1184	1186	HR
O	1187	1188	2
O	1188	1189	.
O	1189	1191	85
O	1191	1192	;
O	1193	1195	95
O	1196	1197	%
O	1198	1201	CI1
O	1201	1202	.
O	1202	1204	21
O	1204	1205	–
O	1205	1206	6
O	1206	1207	.
O	1207	1209	74
O	1209	1210	)
O	1211	1219	compared
O	1220	1224	with
O	1225	1228	TEC
O	1229	1236	regimen
O	1236	1237	,
O	1238	1243	which
O	1244	1247	was
O	1248	1252	more
O	1253	1261	apparent
O	1262	1264	in
O	1265	1271	triple
O	1272	1280	negative
O	1281	1288	subtype
O	1288	1289	.

O	1290	1296	Severe
B-outcome	1297	1304	adverse
I-outcome	1305	1310	event
I-outcome	1311	1316	rates
O	1317	1321	were
O	1322	1329	similar
O	1329	1330	,
O	1331	1337	except
O	1338	1342	that
O	1343	1351	patients
O	1352	1359	treated
O	1360	1364	with
O	1365	1368	TEC
O	1369	1372	had
O	1373	1374	a
O	1375	1381	higher
O	1382	1386	rate
O	1387	1389	of
B-outcome	1390	1401	neutropenia
I-outcome	1402	1405	and
I-outcome	1406	1416	leucopenia
O	1416	1417	.

O	1418	1421	TEC
O	1422	1431	treatment
O	1432	1435	had
O	1436	1437	a
O	1438	1446	superior
O	1447	1455	survival
O	1456	1463	outcome
O	1464	1467	and
O	1468	1473	trend
O	1474	1476	of
O	1477	1483	higher
O	1484	1487	pCR
O	1488	1492	rate
O	1493	1501	compared
O	1502	1506	with
O	1507	1509	TC
O	1510	1512	in
O	1513	1517	this
O	1518	1523	trial
O	1524	1531	setting
O	1531	1532	,
O	1533	1543	especially
O	1544	1546	in
O	1547	1553	triple
O	1554	1562	negative
O	1563	1570	subtype
O	1570	1571	,
O	1572	1577	which
O	1578	1586	deserves
O	1587	1594	further
O	1595	1605	validation
O	1605	1606	.
